Cancer Res Treat.  2020 Oct;52(4):1162-1177. 10.4143/crt.2020.138.

FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition

Affiliations
  • 1Department of Gastrointestinal Surgery and Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2Department of General Surgery, Tongchuan People's Hospital, Shanxi, China
  • 3Department of Thyroid, and Breast Surgery, Xinxiang Central Hospital, Xinxiang, China
  • 4Department of Infectious Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 5Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Abstract

Purpose
Fibroblast growth factor receptor 4 (FGFR4) plays a critical role in cancer progression involving in tumor proliferation, invasion, and metastasis. This study clarified the role of FGFR4-Arg388 variant in gastric cancer (GC), and more importantly highlighted the possibility of this single nucleotide polymorphism (SNP) as potential therapeutic targets.
Materials and Methods
FGFR4 polymorphism was characterized in advanced GC patients to perform statistical analysis. FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines.
Results
Among 102 GC patients, the FGFR4-Arg388 patients showed significantly higher tumor stage (p=0.047) and worse overall survival (p=0.033) than the Gly388 patients. Immunohistochemical results showed that FGFR4-Arg388 patients were more likely to have higher vimentin (p=0.025) and p-STAT3 (p=0.009) expression compared with FGFR4-Gly388 patients. In transfected GC cells, the overexpression of FGFR4-Arg388 variant increased proliferation and invasion of GC cells, increasing resistance of GC cells to OXA compared with cells overexpressing the Gly388 allele.
Conclusion
The exploration mechanism may be through FGFR4-Arg388/STAT3/epithelial to mesenchymal transition axis regulating pivotal oncogenic properties of GC cells. The FGFR4-Arg388 variant may be a biomarker and a candidate target for adjuvant treatment of GC.

Keyword

Fibroblast growth factor receptor 4; Gly388Arg polymorphism; Gastric neoplasms; STAT3; Epithelial to mesenchymal transition

Figure

  • Fig. 1. (A) Gene sequencing including three specific fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphic genotype (including Gly/Gly, Gly/Arg, and Arg/Arg). (B) Significant difference was observed between patients with FGFR4-Gly388 allele and FGFR4-Arg388 variant among 102 gastric cancer (GC) patients after stratified Kaplan-Meier survival analysis. (C) Strong positive expressions of immunohistochemical markers in GC tissue were demonstrated. All H&E staining and immunohistochemical pictures were amplified 200-fold (upper) and 400-fold (lower).

  • Fig. 2. The expressions of fibroblast growth factor receptor 4 (FGFR4) mRNA and protein were illustrated in various gastric cancer (GC) cell lines and transfected cells. (A) Expressions of FGFR4 protein in different GC cell lines by western blot. (B) Expressions of FGFR4 mRNA in different GC cells by reverse transcription polymerase chain reaction (RT-PCR). (C) Expressions of FGFR4 mRNA in different GC cells by quantitative real-time polymerase chain reaction (q-PCR). Expressions of FGFR4 mRNA in SGC7901 (D) and BGC803 (E) cells (mock, negative control [NC], Gly388-transfected, and Arg388-transfected) by RT-PCR. Expressions of FGFR4 mRNA in SGC7901 (F) and BGC803 (G) cells (mock, NC, Gly388-transfected, and Arg388-transfected) by q-PCR. β-Actin was served as loading control. At least three independent detecting were performed. *p < 0.05.

  • Fig. 3. Effect of fibroblast growth factor receptor 4 (FGFR4) genotype on proliferation, invasion, and migration. (A, B) Compared with mock and negative control (NC) cells, the proliferation of Gly388- and Arg388-transfected cells was significantly enhanced. In addition, Arg388-transfected cells have a faster proliferation than Gly388-transfected cells. In addition, Arg388-transfected cells have a faster proliferation than Gly388-transfected cells. Similar results were also observed in the EdU fluorescence staining test (C-F), Transwell chambers invasion assay (G-J), and cell scratch assay (K-N). *p < 0.05. Similar results were also observed in the EdU fluorescence staining test (C-F), Transwell chambers invasion assay (G-J), and cell scratch assay (K-N). *p < 0.05.

  • Fig. 4. The relationship between fibroblast growth factor receptor 4 (FGFR4) genotype and oxaliplatin (OXA) resistance. (A-D) Effects of different OXA concentrations on the activity of SGC7901 and BGC803 cells. NC, normal control. (E-H) Flow cytometry: apoptosis rate of gastric cancer (GC) cells with different FGFR4 genotypes after OXA addition for 24 hours. (I-L) Fluorescent staining for apoptosis of GC cells with different FGFG4 genotypes (green represents early apoptosis and red represents apoptosis death). PI, propidium iodide. (M, N) Western bolt was used to detect the changes of apoptosis molecules in GC cells with different FGFG4 genotypes before and after OXA addition. *p < 0.05.

  • Fig. 5. The mechanism of fibroblast growth factor receptor 4 (FGFR4)-Arg388 influencing the oncogenic properties of gastric cancer cells. (A, B) Western blot detection of the expression of related molecules including FGFR4, signal pathway (STAT3), and epithelial to mesenchymal transition (E-cadherin and vimentin) in SGC7901 and BGC803 cells with different FGFG4 genotypes (mock, normal control [NC], Gly388, and Arg388). (C, D) The changes of related molecules between overexpression Gly388- and Arg388-transfected cells were detected, when cells were incubated with the Jak2 inhibitor AG490 to block STAT3 activation.


Reference

References

1. Katoh M. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther. 2010; 10:1375–9.
Article
2. Li J, Ye Y, Wang M, Lu L, Han C, Zhou Y, et al. The overexpression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer. Tumour Biol. 2016; 37:6881–91.
Article
3. Ye Y, Jiang D, Li J, Wang M, Han C, Zhang X, et al. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer. Tumour Biol. 2016; 37:3185–95.
Article
4. Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, et al. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol. 2010; 17:3354–61.
Article
5. Chou CH, Hsieh MJ, Chuang CY, Lin JT, Yeh CM, Tseng PY, et al. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget. 2017; 8:96225–38.
Article
6. Ezzat S, Wang R, Pintilie M, Asa SL. FGFR4 polymorphic alleles modulate mitochondrial respiration: a novel target for somatostatin analog action in pituitary tumors. Oncotarget. 2017; 8:3481–94.
Article
7. Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, et al. A polymorphism in the FGFR4 gene is associated with risk of neuroblastoma and altered receptor degradation. J Pediatr Hematol Oncol. 2016; 38:131–8.
Article
8. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003; 98:2245–50.
Article
9. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer. 2006; 94:1879–86.
Article
10. Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J, et al. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res. 2011; 17:4355–66.
Article
11. Jalali S, Monsalves E, Tateno T, Zadeh G. Role of mTOR inhibitors in growth hormone-producing pituitary adenomas harboring different FGFR4 genotypes. Endocrinology. 2016; 157:3577–87.
Article
12. Ulaganathan VK, Ullrich A. Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants. Mol Cell Oncol. 2016; 3:e1145176.
Article
13. Ezzat S, Zheng L, Florez JC, Stefan N, Mayr T, Hliang MM, et al. The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. Cell Metab. 2013; 17:929–40.
14. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, et al. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A. 2010; 107:15786–91.
Article
15. Cho SH, Hong CS, Kim HN, Shin MH, Kim KR, Shim HJ, et al. FGFR4 Arg388 is correlated with poor survival in resected colon cancer promoting epithelial to mesenchymal transition. Cancer Res Treat. 2017; 49:766–77.
Article
16. Quintanal-Villalonga A, Ojeda-Marquez L, Marrugal A, Yague P, Ponce-Aix S, Salinas A, et al. The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction. Sci Rep. 2018; 8:2394.
Article
17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–4.
Article
18. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006; 24:3747–55.
Article
19. Myoteri D, Dellaportas D, Lykoudis PM, Apostolopoulos A, Marinis A, Zizi-Sermpetzoglou A. Prognostic evaluation of vimentin expression in correlation with Ki67 and CD44 in surgically resected pancreatic ductal adenocarcinoma. Gastroenterol Res Pract. 2017; 2017:9207616.
Article
20. Gao H, Lan X, Li S, Xue Y. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumour Biol. 2017; 39:1010428317698368.
Article
21. Zhang S, Huang S, Deng C, Cao Y, Yang J, Chen G, et al. Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients. Oncotarget. 2017; 8:18848–60.
Article
22. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, et al. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012; 72:5683–91.
Article
23. Quintanal-Villalonga A, Carranza-Carranza A, Melendez R, Ferrer I, Molina-Pinelo S, Paz-Ares L. Prognostic role of the FGFR4-388Arg variant in lung squamous-cell carcinoma patients with lymph node involvement. Clin Lung Cancer. 2017; 18:667–74.
Article
24. Shim HJ, Shin MH, Kim HN, Kim JH, Hwang JE, Bae WK, et al. The prognostic significance of FGFR4 Gly388 polymorphism in esophageal squamous cell carcinoma after concurrent chemoradiotherapy. Cancer Res Treat. 2016; 48:71–9.
25. Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017; 36:8.
Article
26. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003; 197:157–68.
27. Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res. 2006; 12:3902–7.
Article
28. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009; 28:2940–7.
Article
29. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008; 283:14665–73.
Article
30. Zang C, Liu X, Li B, He Y, Jing S, He Y, et al. IL-6/STAT3/TWIST inhibition reverses ionizing radiation-induced EMT and radioresistance in esophageal squamous carcinoma. Oncotarget. 2017; 8:11228–38.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr